Background {#Sec1}
==========

Cystinuria (OMIM 220100) is a congenital disorder characterized by the defective renal reabsorption of cystine and other dibasic amino acids in the proximal renal tubule and in the epithelial cells of the gastrointestinal tract (for review: \[[@CR1]\]). The resulting hyperexcretion of cystine leads to its precipitation in the distal tubule and formation of cystine stones. In adults cystine stones account for only 1--2% of all nephrolithiasis patients, whereas cystine stones account for 6--8% of pediatric urolithiasis patients \[[@CR2]\].

So far, two autosomal genes have been identified to harbor genetic variants causing cystinuria. The *SLC3A1*/*rBAT* gene in 2p21 encodes the heavy subunit of the heterodimeric rBAT-b^0,+^AT transporter, the light chain is encoded by the *SLC7A9*/ *b*^*0,+*^*AT* gene in 19q12 \[[@CR3]--[@CR7]\]. The transporter is localized in the apical membrane of proximal tubules in the kidney and mediates the reabsorption of cystine, arginine, ornithine and lysine. Genomic variants in both genes have been identified in cystinuria patients. Whereas mutations in *SLC3A1* are commonly inherited in an autosomal recessive manner, *SLC7A9* alterations show a broad variability of inheritance, ranging from autosomal recessive to dominant. In some patients large genomic deletions in 2p21 affecting the *SLC3A1* gene and its neighbored *PREPL* gene can be detected, in that case urolithiasis is associated with hypotonia and further clinical symptoms (Hypotonia-Cystinuria syndrome - HCS, OMIM 606407).

Comprehensive mutation analyses in both genes allow the detection of genetic variants in more than 85% of patients, but a significant number of patients currently remain without a molecular diagnosis. In fact, the lack to detect pathogenic mutations can be explained by the applied methods and their different sensitivities, the influence of the ethnic origin on the distribution of mutations, and the autosomal dominant impact of some mutations in *SLC7A9* (and *SLC3A1*). However, they do not explain that a significant number of patients remains without any detectable mutation.

This observation as well as results of expression studies in the proximal renal tubule for rBAT and b^0,+^AT indicated that further subunits of the plasma membrane protein rBAT are involved in the renal cystine reabsorption. In particular, the opposing expression of rBAT and b^0,+^AT with a decline of rBAT expression from S3 towards the S1 segment and vice versa points to the existence of a further factor. With AGT1 as the second partner of rBAT in the S3 segment, the long-postulated partner of rBAT in the S3 segment of the renal proximal tubule cystine transport has recently been identified \[[@CR8]\].

Consequently, *AGT1/ SLC7A13* has been suggested as a further candidate gene for cystinuria, mutations in this factor might explain the so far unsolved cases of cystinuria in which mutations in *SC3A1* and *SLC7A9* had been excluded. We here report on the results of our search for pathogenic genetic variants in *SLC7A13* in a cohort of 17 patients without disease-causing variations in the known cystinuria genes.

Methods {#Sec2}
=======

In total, 103 patients from Germany, Turkey, Greece, Italy and Eastern Europe had been ascertained in precedent studies \[[@CR9]--[@CR15]\] aiming on the identification of *SLC3A1* and *SLC7A9* variants or in the course of routine molecular diagnostics of cystinuria because of (recurrent) nephrolithiasis or cystinuria. The study had been approved by the ethical committee of the Medical Faculty at the University Hospital Aachen (RWTH Aachen, EK302--16), Germany.

Analyses for disease-causing variants in *SLC3A1* and *SLC7A9* comprised Sanger sequencing analysis of their coding regions and the intron-exon boundaries (NM_000341.3, NM_014270.4), and search for whole exon deletions and duplications by multiplex ligation probe-dependent amplification (MLPA; kit P426-A1, mrc Holland, Amsterdam/NL).

The coding exons and the neighboring intron regions of *SCL7A13* (NM_138817.2) were analyzed by Sanger sequencing after PCR amplification. Primers are listed in Table [1](#Tab1){ref-type="table"}, PCR as well as sequencing conditions are available on request.Table 1Primers used for Sanger sequencing of the coding sequences and exon-intron boundaries of the *SLC7A13* geneExonFoward PrimerReverse PrimerLength of PCR product1SLC7A13_1.1F: CTTTGCAGCTACATAGGCAGG\
SLC7A13_1.2F: TGGACATCCTTGTTTCTGGGGSLC7A13_1.1R: TAGGCAGCTTTGGGACAGAG\
SLC7A13_1.2R: GGCTGGCATGATCTGATTCAG471\
5372SLC7A13_2F: TAAAATCATGCTTGTACCCCSLC7A13_2R: AACAGTGGTTCTGACTGGTG3303SLC7A13_3F: TCATTAGTATTTCTCTTTTAACACSLC7A13_3R: TGTGTTTCACAGTAACTGAG5414SLC7A13_4F: TGCAGGTATCATTCATGGATGTTCSLC7A13_4R: TGTTTAACCTTGATTTGGAATCTG367

Results {#Sec3}
=======

In 103 cystinuria patients, 83.5% had at least one *SLC3A1* or *SLC7A9* mutation (Table [2](#Tab2){ref-type="table"}). In 49.5% (*n* = 51) of patients, two mutations could be observed, either as homozygosity / compound heterozygosity in one of the two genes or as mixed heterozygosity in both genes. In 17.5% (*n* = 18), one mutation was detected for which a penetrance in heterozygous state can be expected, i.e. the duplication of exons 5 to 9 in *SLC3A1* or *SLC7A9* mutations. In 16.5% (*n* = 17), only one mutation in *SLC3A1* was identified which would not explain the phenotype, in these cases a second mutation can be expected but is still undetected. In two patients we identified homozygosity / compound heterozygosity for large 2p21 deletions, these patients were molecularly diagnosed as HCS as both *SLC3A1* and *PREPL* were affected.Table 2Summary of the mutation detection results for *SLC3A1* and *SLC7A9* in a cohort of 103 cystinuria patientstwo mutationsone mutation explaining cystinuria^a^only one mutationno mutation*SLC3A1*39°217/*SLC7A9*1116//mixed1///total51 (49.5%)18 (17.5%)17 (16.5%)17 (16.5%)^a^heterozygosity of the duplication of exons 5 to 9 in *SLC3A1* and of *SLC7A9* mutations without parallel occurrence of a second mutation has been reported to be sufficient to cause cystinuria; °including large HCS deletions

Mutation analysis for the two genes was negative in 16.5% of patients, and these 17 individuals (Table [3](#Tab3){ref-type="table"}) were screened for pathogenic mutations in the coding sequences and the intron-exon boundaries of *SLC7A13*. However, with the exception of already known apathogenic polymorphisms (rs7814198, rs4419794, rs4621787, rs4546639, rs202114931, rs56993779, rs9656982) we did not detect any pathogenic genetic variant.Table 3Overview on the 17 patients screened for *SLC7A13* mutationspatientethnic originage at first stoneage at examinationnumber of recurrent stonespublished inCys3Italian4 m12 y5--10\[[@CR9]\]Cys4Italian1 y5 y\< 5\[[@CR9]\]Cys21Italian--23 ynone\[[@CR9]\]Cys23TurkishNA30 y\< 5\[[@CR10]\]Cys43German19 y51 y\> 10\[[@CR10]\]Cys58Turkish6 y16 y\< 5\[[@CR14]\]Cys63German13 m3 y5--10\[[@CR14]\]Cys89Russian25 y30 y\< 5\[[@CR14]\]Cys98German3.5 y5 y\< 5\[[@CR14]\]Cys105Russian1.5 y12 y5--10\[[@CR14]\]Cys116Turkish1.5 y11 y5--10\[[@CR12]\]Cys128Turkish17 y23 y\> 10\[[@CR12]\]Cys152GermanNANANA\[[@CR12]\]Cys161Turkish1 m1 m1\[[@CR12]\]Cys181Polish3 y9 y\> 10\[[@CR13]\]Cys183Polish6 y6 y5--10\[[@CR13]\]M20679GermanNA52 y1--Mutations in the *SLC3A1* and *SLC7A9* genes had been excluded before (see texts). The majority of patients was in included in precedent studies. (*NA* not assessed; *y* year, *m* months)

Discussion {#Sec4}
==========

In contrast to the majority of kidney stones which occur sporadically, cystine stone formation and cystinuria have been suggested to be exclusively caused by genomic mutations. This assumption was supported by the identification of mutations in cystinuria patients in the genes coding the two subunits of the renal rBAT-b^0,+^AT transporter. However, with the exception of populations with founder mutations (e.g. \[[@CR16]\]), the detection rate for mutations in the *SLC3A1* and *SLC7A9* genes never reaches 100%, and genetic variants in both genes account for 80--85% in the cystinuria population. This incomplete detection rate is certainly caused by methodological restrictions as non-coding regions (introns, promotor region) of the genes are commonly not investigated and the applied methods show different sensitivities. Furthermore, the penetrance of some mutations in both genes differs from the classical modes of Mendelian inheritance. In case of *SLC3A1*, mutations are generally autosomal recessively inherited, but at least the duplication of exons 5 to 9 in this gene has been suggested to function as an autosomal dominant allele \[[@CR17]\]. For *SLC7A9* the situation is more complex, in this gene mutations can have both recessive as well as dominant effects. Thus, an autosomal dominant inheritance with incomplete penetrance has been suggested for variants in *SLC7A9*. In summary, the uncertainties to classify mutations in the already known cystinuria genes make the decision on the final detection rate difficult. Furthermore, it can be asked whether the detection of only one mutated allele in *SLC3A1* or *SLC7A9* is indeed sufficient to explain the cystinuria phenotype, or whether a second genomic variant in the same or another gene is required.

In addition to this unclear situation in patients with only one disease-causing mutation, there remains a considerable ratio of patients without a mutation in both genes. This observation provides strong evidence for the existence of a further factor mutations in which might cause cystinuria, but precedent mutation detection analyses in different candidate genes did not provide evidence for their involvement in the etiology of the disease (e.g. *SLC1A5*/ ATB(0), *SLC7A10*/ASC-1) \[[@CR14], [@CR18]--[@CR21]\]. The recently described novel cystine transporter *SLC7A13*/AGT1 in the renal proximal tubule was a promising candidate to harbor pathogenic mutations in cystinuria patients. In particular, the observation that AGT1 serves as the second partner of the rBAT transporter in the S3 segment and its expression is consistent with the inversed expression of the so far known cystine transporter subunits *SLC3A1*/rBAT and *SLC7A9*/ b^0,+^AT \[[@CR8]\] strongly points to *SLC7A13* as a candidate gene for cystinuria.

Despite these strong evidences, we could not confirm a relevant role of *SLC7A13* as a third gene contributing to the pathology of cystinuria. In our cohort which was comprehensively analysed for *SLC3A1* and *SLC7A9* variants, we could not detect any pathogenic mutation in the coding sequences and intron-exon boundaries of *SLC7A13*. In fact, we cannot exclude large deletions or duplications affecting whole exons, or variants in the non-coding regions of the gene. However, these types of mutations generally contribute only to a small proportion of the mutation spectrum of inherited diseases.

With the exclusion of *SLC7A13*/AGT1 as the third cystinuria gene, the question remains unanswered why analysis for the two cystinuria genes *SLC3A1* and *SLC7A9* succeeds only in up to 85%. In fact, this finding can be explained by ethnic differences in the distribution of mutations, and by methodological limitations. However, the comprehensive analysis for *SLC3A1* and *SLC7A9* mutations in a large number of studies (for review see: \[[@CR1], [@CR22]\]) does not indicate that a considerable number of genomic mutations in *SLC3A1* or *SLC7A9* has been missed. We therefore postulate that there is another genomic factor causing cystinuria. This factor might either been another so far unknown renal cystine transportert, or a genomic predisposition factor like a frequent polymorphism in one of the already known genes which -- in combination with other predisposing elements (other genomic variants, life style) - causes the disease.

Conclusion {#Sec5}
==========

With the exclusion of *SLC7A13*/AGT1 as the third cystinuria gene accounting for the *SLC3A1* and *SLC7A9* mutation negative cases, it becomes obvious that other genetic factors should be responsible for the cystinuria phenotype in nearly 15% of patients.
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